Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RBM-007 in Exudative Age-Related Macular Degeneration (SUSHI)
NCT03633084Phase 2Completed
- Sponsor
- Ribomic Inc.
- Start
- Aug 2018
- Primary completion
- Jun 2019
- Modality
- RNA Aptamers, DNA Aptamers
- Countries
- 1
01
Overview
A Phase 2 trial of umedaptanib pegol in exudative age-related macular degeneration, sponsored by Ribomic Inc.. Started Aug 2018; status: completed.
02
Drugs
umedaptanib pegol
03
Conditions
exudative age-related macular degeneration
Beyond the preview
Go deeper on NCT03633084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03633084.